LIVIVO - Search results -

Search results

Result 1 - 10 of total 71

Search options

Article ; Online: New biologics for food allergy.

Schuetz, Jackson P / Anderson, Brent / Sindher, Sayantani B

Current opinion in allergy and clinical immunology

2024 Volume 24, Issue 3, Page(s) 147–152

Abstract: Purpose of review: This review aims to explore role of emerging biologics, including ligelizumab, UB-221, dupilumab, and antialarmins, in food allergy management. With a focus on recent developments, we evaluate their promise in mitigating adverse ... ...

Abstract	Purpose of review: This review aims to explore role of emerging biologics, including ligelizumab, UB-221, dupilumab, and antialarmins, in food allergy management. With a focus on recent developments, we evaluate their promise in mitigating adverse events during oral immunotherapy (OIT), reducing allergic reactions, and addressing the limitations of current therapeutic options. Recent findings: Antiimmunoglobulin E mAbs, exemplified by omalizumab, demonstrate efficacy in desensitization and safety improvement during multiallergen OIT. Next-generation antibodies like ligelizumab and UB-221 exhibit enhanced potency and unique mechanisms, holding promise for food allergy treatment. Dupilumab, targeting IL-4 receptor alpha, presents potential benefits in decreasing allergen-specific IgE and modifying the atopic march. Exploration of antialarmins, specifically anti-IL-33 (etokimab) and anti-TSLP (tezepelumab), reveals encouraging results, with etokimab showing early success in peanut allergy trials. Summary: Biologics hold promising potential for food allergy treatment. Tailoring therapeutic approaches based on shared decision-making becomes pivotal. While omalizumab remains a significant option, next-generation anti-IgE antibodies and agents targeting alarmins exhibit unique strengths. Dupilumab, despite limited success as monotherapy, shows promise as an adjunct for OIT. Careful consideration of treatment goals, patient preferences, and the evolving landscape of biologics will shape future clinical practice, offering allergists an expanded toolbox for personalized food allergy management.
MeSH term(s)	Humans ; Food Hypersensitivity/immunology ; Food Hypersensitivity/therapy ; Food Hypersensitivity/drug therapy ; Biological Products/therapeutic use ; Biological Products/adverse effects ; Desensitization, Immunologic/methods ; Animals ; Anti-Allergic Agents/therapeutic use ; Immunoglobulin E/immunology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Allergens/immunology ; Omalizumab/therapeutic use
Chemical Substances	Biological Products ; Anti-Allergic Agents ; Immunoglobulin E (37341-29-0) ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal ; Allergens ; Omalizumab (2P471X1Z11)
Language	English
Publishing date	2024-03-28
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2088710-3
ISSN	1473-6322 ; 1528-4050
ISSN (online)	1473-6322
ISSN	1528-4050
DOI	10.1097/ACI.0000000000000981
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5666: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Editorial comments on "Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants-The STOP-AD randomized controlled trial"-Is emollient therapy enough?

Brough, Helen A / Sindher, Sayantani / Nadeau, Kari C

Allergy

2022 Volume 78, Issue 4, Page(s) 908–911

MeSH term(s)	Humans ; Infant ; Dermatitis, Atopic/drug therapy ; Dermatitis, Atopic/prevention & control ; Emollients/therapeutic use ; Treatment Outcome ; Randomized Controlled Trials as Topic
Chemical Substances	Emollients
Language	English
Publishing date	2022-12-26
Publishing country	Denmark
Document type	Editorial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
ZDB-ID	391933-x
ISSN	1398-9995 ; 0105-4538
ISSN (online)	1398-9995
ISSN	0105-4538
DOI	10.1111/all.15626
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.150: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 125: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Providing a Safe Nest for Improved Health Care Outcomes in Pregnant Women With Asthma.

Sindher, Sayantani B / Fast, Katharine / Nadeau, Kari C / Chinthrajah, R Sharon

The journal of allergy and clinical immunology. In practice

2022 Volume 10, Issue 7, Page(s) 1784–1787

Abstract: There is a large unmet disease burden arising from asthma in pregnancy. Pregnant women affected by moderate to severe asthma have an increased risk for adverse perinatal outcomes. This can be worsened by social determinants of health, which are social ... ...

Abstract	There is a large unmet disease burden arising from asthma in pregnancy. Pregnant women affected by moderate to severe asthma have an increased risk for adverse perinatal outcomes. This can be worsened by social determinants of health, which are social and environmental conditions that affect health and the quality of life. Here we present the case of a medically complex pregnant woman with worsening asthma and challenges in optimizing positive outcomes for both the mother and baby during the perinatal period. This case captures several elements of social determinants of health that affect health outcomes most notably in non-White patients, including chronic exposure to air pollution contributing to asthma severity and reduced access to health care specialists.
MeSH term(s)	Asthma/epidemiology ; Asthma/therapy ; Delivery of Health Care ; Female ; Humans ; Pregnancy ; Pregnancy Complications ; Pregnancy Outcome ; Pregnant Women ; Quality of Life
Language	English
Publishing date	2022-03-17
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2843237-X
ISSN	2213-2201 ; 2213-2198
ISSN (online)	2213-2201
ISSN	2213-2198
DOI	10.1016/j.jaip.2022.03.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 7086: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Treatment of food allergy: Oral immunotherapy, biologics, and beyond.

Sindher, Sayantani B / Hillier, Claire / Anderson, Brent / Long, Andrew / Chinthrajah, R Sharon

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

2023 Volume 131, Issue 1, Page(s) 29–36

Abstract: The prevalence of food allergy (FA) has been increasing globally and comes with a heavy burden not just economically, but also on quality of life. Although oral immunotherapy (OIT) is effective at inducing desensitization to food allergens, it has ... ...

Abstract	The prevalence of food allergy (FA) has been increasing globally and comes with a heavy burden not just economically, but also on quality of life. Although oral immunotherapy (OIT) is effective at inducing desensitization to food allergens, it has several limitations that weaken its success. Limitations include a long duration of build-up, especially when used for multiple allergens, and a high rate of reported adverse events. Furthermore, OIT may not be effective in all patients. Efforts are underway to identify additional treatment options, either as monotherapy or in combination, to treat FA or enhance the safety and efficacy of OIT. Biologics such as omalizumab and dupilumab, which already have US Food and Drug Administration approval for other atopic conditions have been the most studied, but additional biologics and novel strategies are emerging. In this review, we discuss therapeutic strategies including immunoglobulin E inhibitors, immunoglobulin E disruptors, interleukin-4 and interleukin-13 inhibitors, antialarmins, JAK1 and BTK inhibitors, and nanoparticles, and the data surrounding their application in FA and highlighting their potential.
MeSH term(s)	Humans ; Desensitization, Immunologic/adverse effects ; Biological Products/therapeutic use ; Quality of Life ; Administration, Oral ; Food Hypersensitivity ; Immunotherapy ; Allergens ; Immunoglobulin E
Chemical Substances	Biological Products ; Allergens ; Immunoglobulin E (37341-29-0)
Language	English
Publishing date	2023-04-25
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, N.I.H., Extramural
ZDB-ID	1228189-x
ISSN	1534-4436 ; 0003-4738 ; 1081-1206
ISSN (online)	1534-4436
ISSN	0003-4738 ; 1081-1206
DOI	10.1016/j.anai.2023.04.023
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.136: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Neuroimmune pathways and allergic disease: An overview.

Long, Andrew / Ferretti-Gallon, Jenika Josephine / Chin, Andrew Ryan / Chinthrajah, R Sharon / Sindher, Sayantani Bhattacharya

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

2023 Volume 131, Issue 5, Page(s) 547–549

MeSH term(s)	Humans ; Hypersensitivity ; Neuroimmunomodulation
Language	English
Publishing date	2023-07-28
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	1228189-x
ISSN	1534-4436 ; 0003-4738 ; 1081-1206
ISSN (online)	1534-4436
ISSN	0003-4738 ; 1081-1206
DOI	10.1016/j.anai.2023.06.029
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.136: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Recent Mechanistic Studies in Allergic Diseases.

Sindher, Sayantani B / Sharma, Reyna / Yarlagadda, Medha / Chin, Andrew R / Chinthrajah, R Sharon

International journal of molecular sciences

2023 Volume 24, Issue 18

Abstract: Allergic diseases, such as food allergies, asthma, and allergic rhinitis, continue to present a significant challenge for a broad cross-section of the population, despite recent advancements in their treatment and prevention [ ... ]. ...

Abstract	Allergic diseases, such as food allergies, asthma, and allergic rhinitis, continue to present a significant challenge for a broad cross-section of the population, despite recent advancements in their treatment and prevention [...].
MeSH term(s)	Humans ; Prevalence ; Rhinitis, Allergic/therapy ; Asthma/therapy ; Asthma/epidemiology ; Food Hypersensitivity/therapy ; Food Hypersensitivity/epidemiology
Language	English
Publishing date	2023-09-20
Publishing country	Switzerland
Document type	Editorial
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms241814312
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The Role of Biologics in the Treatment of Food Allergy.

Sindher, Sayantani B / Fiocchi, Alessandro / Zuberbier, Torsten / Arasi, Stefania / Wood, Robert A / Chinthrajah, R Sharon

The journal of allergy and clinical immunology. In practice

2023 Volume 12, Issue 3, Page(s) 562–568

Abstract: The landscape of food allergy (FA) treatment is poised for a paradigm shift with the emergence of biologic therapies. The Food and Drug Administration approval of a standardized peanut powder for oral immunotherapy in 2020 marked a milestone, signaling a ...

Abstract	The landscape of food allergy (FA) treatment is poised for a paradigm shift with the emergence of biologic therapies. The Food and Drug Administration approval of a standardized peanut powder for oral immunotherapy in 2020 marked a milestone, signaling a departure from allergen avoidance toward proactive treatment strategies. Although oral immunotherapy has been proven effective in desensitizing patients to specific allergens, there are several limitations such as lacking standardization, a long-time commitment to achieve maintenance, and adverse events. Biologics, including omalizumab, dupilumab, and antialarmins, have shown promise in treating various allergic diseases, including FA. These biologics target the underlying immunologic pathways driving allergic reactions, offering an antigen-agnostic approach. Omalizumab (anti-IgE) has been the most studied biologic in this space and can be used both as an adjunct therapy with oral immunotherapy and as monotherapy. Dupilumab targeting IL-4 and IL-13 also shows promise as an adjunct therapy. The emergence of antialarmins further broadens the spectrum of FA treatment possibilities. Biologics represent a transformative approach to FA treatment, directly addressing the underlying mechanisms. Future research should focus on patient selection criteria, personalized biomarker panels, optimal timing of intervention, and treatment durations.
MeSH term(s)	Humans ; Omalizumab/therapeutic use ; Desensitization, Immunologic/adverse effects ; Food Hypersensitivity/drug therapy ; Food Hypersensitivity/etiology ; Food ; Allergens ; Biological Products/therapeutic use ; Administration, Oral
Chemical Substances	Omalizumab (2P471X1Z11) ; Allergens ; Biological Products
Language	English
Publishing date	2023-11-25
Publishing country	United States
Document type	Journal Article
ZDB-ID	2843237-X
ISSN	2213-2201 ; 2213-2198
ISSN (online)	2213-2201
ISSN	2213-2198
DOI	10.1016/j.jaip.2023.11.032
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7086: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Current insights: a systemic review of therapeutic options for peanut allergy.

O'Rourke, Eimear / Tang, Hilary / Chin, Andrew / Long, Andrew / Sindher, Sayantani / Chinthrajah, R Sharon

Current opinion in allergy and clinical immunology

2022 Volume 22, Issue 3, Page(s) 188–193

Abstract: Purpose of review: With increasing prevalence of peanut allergy (PA) globally and the greater risk of potential reactions occurring due to the leading role of nuts in food products, PA has become a significant public health concern over the past decade, ...

Abstract	Purpose of review: With increasing prevalence of peanut allergy (PA) globally and the greater risk of potential reactions occurring due to the leading role of nuts in food products, PA has become a significant public health concern over the past decade, affecting up to 5 million of the US adult population. This review details updates and advances in prevalence, diagnosis, and immunotherapies that have occurred over the past year. Recent findings: Therapeutic and diagnostic advances remain at the forefront of research and have continued to push the food allergy (FA) field forward to provide a promising role in the detection and treatment of PA. The FA field has researched significant advances in peanut immunotherapy, biomarker diagnosis, and quality of life (QoL) improvement. Summary: Given the burden and consequences for individuals with PA, these advances delivered in clinical practice can significantly improve the QoL of individuals with PA and their caregivers. Ongoing studies will continue to investigate long-term outcome measures of desensitisation and effective management plans tailored to the families' needs.
MeSH term(s)	Adult ; Humans ; Arachis ; Food Hypersensitivity ; Immunotherapy ; Peanut Hypersensitivity/diagnosis ; Peanut Hypersensitivity/epidemiology ; Peanut Hypersensitivity/therapy ; Quality of Life
Language	English
Publishing date	2022-03-11
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Systematic Review
ZDB-ID	2088710-3
ISSN	1473-6322 ; 1528-4050
ISSN (online)	1473-6322
ISSN	1528-4050
DOI	10.1097/ACI.0000000000000824
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5666: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Transitioning from epicutaneous to oral peanut immunotherapy.

Wong, Lauren / Kost, Laurie / Anderson, Brent / Long, Andrew / Sindher, Sayantani B / Chinthrajah, R Sharon / Collins, William J

Frontiers in allergy

2023 Volume 4, Page(s) 1089308

Abstract: Introduction: Epicutaneous immunotherapy (EPIT) has been tested in clinical trials for children with peanut allergy (PA) for its safety and efficacy in inducing desensitization. Aside from peanut avoidance and symptom management, oral immunotherapy (OIT) ...

Abstract	Introduction: Epicutaneous immunotherapy (EPIT) has been tested in clinical trials for children with peanut allergy (PA) for its safety and efficacy in inducing desensitization. Aside from peanut avoidance and symptom management, oral immunotherapy (OIT) is another option for PA patients. However, OIT can be associated with adverse events and pose safety concerns to children and their caregivers. Methods: This study assessed 27 children who successfully completed a peanut EPIT trial. 18 of them transitioned to peanut OIT with starting doses ranging from 10-600 mg of peanut protein. Our aim was to learn more about the EPIT to OIT experience through descriptive survey responses and to gather information that may support the sequential use of the two immunotherapies for safe and positive outcomes that may not be achieved by either alone. Results: Overall, children and their caregivers had less anxiety about starting OIT after having had peanut exposure through EPIT. Most children who transitioned from EPIT to OIT had no or minor symptoms initially, with symptoms lessening later in OIT. Most were also able to maintain or increase their peanut dose over time, achieving maintenance doses of 60-2,000 mg. Discussion: In comparison with current literature on OIT for PA in children, the reported symptoms appeared less severe and less prevalent in the EPIT to OIT group. However, there were 3 participants who withdrew from OIT due to the development of intolerable symptoms. This study provides initial data in support of EPIT to OIT, and larger randomized controlled trials assessing effectiveness of the two therapies together are warranted.
Language	English
Publishing date	2023-02-06
Publishing country	Switzerland
Document type	Journal Article
ISSN	2673-6101
ISSN (online)	2673-6101
DOI	10.3389/falgy.2023.1089308
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Food allergy risks and dining industry - an assessment and a path forward.

Stankovich, Gabriel A / Warren, Christopher M / Gupta, Ruchi / Sindher, Sayantani B / Chinthrajah, R Sharon / Nadeau, Kari C

Frontiers in allergy

2023 Volume 4, Page(s) 1060932

Abstract: Food allergies have increased in prevalence over the last few decades and continue to grow. Consumption of even trace amounts of common foods can cause a rapid allergic reaction (generally within minutes) which can be mild to severe to even life- ... ...

Abstract	Food allergies have increased in prevalence over the last few decades and continue to grow. Consumption of even trace amounts of common foods can cause a rapid allergic reaction (generally within minutes) which can be mild to severe to even life-threatening. Eating at restaurants poses a risk of allergic reactions for those with food allergies due to inadequate, inconsistent labeling of allergens in foods. Here, we review food labeling rules and practices in the restaurant industry and compare and contrast it with food labeling for prepackaged foods. We review global and United States trends, and provide a brief historical overview. The paper describes the key legal and economic motivations behind restaurant food labeling. Next, we describe novel risk-driven policies and new biotechnologies that have the potential to change food labeling practices worldwide. Finally, we outline desirable federal regulations and voluntary information disclosures that would positively impact the public health aspects of restaurant food labeling and improve the quality of life for people with severe food allergies.
Language	English
Publishing date	2023-03-29
Publishing country	Switzerland
Document type	Journal Article ; Review
ISSN	2673-6101
ISSN (online)	2673-6101
DOI	10.3389/falgy.2023.1060932
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED